Open AccessMucous membrane pemphigoid (MMP) and its therapeutic strategies
Author(s) -
Nóra Belső,
Lilla Mihályi,
Zsuzsanna Orosz,
Zsuzsanna BataCsörgő
Publication year - 2021
Publication title -
bőrgyógyászati és venerológiai szemle
Language(s) - English
Resource type - Journals
eISSN - 2064-261X
pISSN - 0006-7768
DOI - 10.7188/bvsz.2021.97.4.3
Subject(s) - medicine , dapsone , rituximab , doxycycline , pemphigoid , basement membrane , dermatology , antibody , toxic epidermal necrolysis , mucous membrane , antibiotics , immunology , pathology , bullous pemphigoid , microbiology and biotechnology , biology
Mucous membrane pemphigoid (MMP) is an autoimmune subepithelial blistering disease. Oral and ocular mucosae are the most frequently afected areas, but the nasopharynx, esophagus, larynx and anogenital region can also be involved. It is characterized by linear deposition of IgG, IgA, or C3 along the basement membrane zone. In low-risk cases topical, intralesional corticosteroids are administered, together with anti-infammatory, immunomodulatory (dapsone) drugs or antibiotics (doxycycline). In severe, high-risk cases we apply systemic corticosteroids and immunosuppresive agents, or biological therapies (rituximab and anti-tumour necrosis factor drugs), or combination treatment of rituximab and intravenous immunoglobulins (IVIG)